Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.

doi:10.1002/cncr.35489

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.

Cancer - 15 Dec 2024

Palandri Francesca, Elli Elena M, Morsia Erika, Benevolo Giulia, Tiribelli Mario, Beggiato Eloise, Bonifacio Massimiliano, Farina Mirko, Martino Bruno, Caocci Giovanni, Pugliese Novella, Tieghi Alessia, Crugnola Monica, Binotto Gianni, Cavazzini Francesco, Abruzzese Elisabetta, Iurlo Alessandra, Isidori Alessandro, Bosi Costanza, Guglielmana Veronica, Venturi Marta, Dedola Alessandra, Loffredo Michele, Fontana Gabriele, Duminuco Andrea, Moioli Alessia, Tosoni Luca, Scalzulli Emilia, Cattaneo Daniele, Lemoli Roberto M, Cilloni Daniela, Bocchia Monica, Pane Fabrizio, Heidel Florian H, Vianelli Nicola, Cavo Michele, Palumbo Giuseppe A, Branzanti Filippo, Breccia Massimo

Abstract excerpt

BACKGROUND: Ruxolitinib (RUX) is a JAK1/2 inhibitor approved for the therapy of myelofibrosis (MF) based on clinical trials including only intermediate2-high risk (INT2/HIGH) patients. However, RUX is commonly used in intermediate-1 (INT1) patients, with scarce information on responses and outcome. METHODS: The authors investigated the benefit of RUX in 1055 MF patients, included in the "RUX-MF" retrospective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged

Share to Aged, 80 and over

Share to Mutation

Share to Nitriles

Share to Primary Myelofibrosis

Share to Pyrazoles

Share to Pyrimidines

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 39078647
DOI: 10.1002/cncr.35489
PMCID: PMC11585342

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.PMID 39078647Read ↗

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.Semantic proximity Read ↗

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial.Semantic proximity Read ↗

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study.Semantic proximity Read ↗

Momelotinib therapy for myelofibrosis: a 7-year follow-up.Semantic proximity Read ↗

Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?Semantic proximity Read ↗

Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.Semantic proximity Read ↗

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.Semantic proximity Read ↗

Efficacy of ruxolitinib for myelofibrosis.Semantic proximity Read ↗

How I treat myelofibrosis.Semantic proximity Read ↗

Practical management of myelofibrosis with ruxolitinib.Semantic proximity Read ↗

How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.Semantic proximity Read ↗

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.